Evolus Inc
Company Profile
Business description
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
Contact
520 Newport Center Drive
Suite 1200
Newport BeachCA92660
USAT: +1 949 284-4555
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
322
Stocks News & Analysis
stocks
Megatrend Investing 2025 and beyond: ASX players to capitalise on the clean energy transition
stocks
DeepSeek revelation hits US chip stocks, ASX data centres and uranium
video
What does a weak Aussie dollar mean for investors?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,782.20 | 36.30 | 0.42% |
| CAC 40 | 7,941.64 | 69.16 | 0.88% |
| DAX 40 | 21,727.20 | 89.67 | 0.41% |
| Dow JONES (US) | 44,882.13 | 168.61 | 0.38% |
| FTSE 100 | 8,646.88 | 89.07 | 1.04% |
| HKSE | 20,225.11 | 27.34 | 0.14% |
| NASDAQ | 19,681.75 | 49.43 | 0.25% |
| Nikkei 225 | 39,624.97 | 111.00 | 0.28% |
| NZX 50 Index | 12,987.18 | 58.80 | 0.45% |
| S&P 500 | 6,071.17 | 31.86 | 0.53% |
| S&P/ASX 200 | 8,524.20 | 30.50 | 0.36% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |